Pain,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 4, 2025
Abstract
Immune
cells
play
a
critical
role
in
the
transition
from
acute
to
chronic
pain.
However,
of
mast
pain
remains
underinvestigated.
Here,
we
demonstrated
that
resolution
inflammatory
is
markedly
delayed
cell–deficient
mice.
In
response
complete
Freund
adjuvant,
mice
showed
greater
levels
nitric
oxide,
leukocyte
infiltration,
and
altered
cytokine/chemokine
profile
inflamed
skin
both
sexes.
wild-type
mice,
number
cell
cell–derived
chymases,
chymase
1
(CMA1)
protease
4
(MCPT4),
increased
skin.
Inhibiting
enzymatic
activity
Consistently,
local
pharmacological
administration
recombinant
CMA1
MCPT4
promoted
hypersensitivity
attenuated
upregulation
cytokines
chemokines
under
inflammation.
We
identified
CCL9
as
target
MCPT4.
Inhibition
recruitment
CD206
+
myeloid
alleviated
Our
work
reveals
new
chymases
preventing
suggests
therapeutic
avenues
for
treatment
Cell Reports,
Journal Year:
2024,
Volume and Issue:
43(2), P. 113685 - 113685
Published: Jan. 22, 2024
Tumor
necrosis
factor
α
(TNF-α)
is
a
major
pro-inflammatory
cytokine,
important
in
many
diseases,
that
sensitizes
nociceptors
through
its
action
on
variety
of
ion
channels,
including
voltage-gated
sodium
(Na
Pain,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 4, 2025
Abstract
Immune
cells
play
a
critical
role
in
the
transition
from
acute
to
chronic
pain.
However,
of
mast
pain
remains
underinvestigated.
Here,
we
demonstrated
that
resolution
inflammatory
is
markedly
delayed
cell–deficient
mice.
In
response
complete
Freund
adjuvant,
mice
showed
greater
levels
nitric
oxide,
leukocyte
infiltration,
and
altered
cytokine/chemokine
profile
inflamed
skin
both
sexes.
wild-type
mice,
number
cell
cell–derived
chymases,
chymase
1
(CMA1)
protease
4
(MCPT4),
increased
skin.
Inhibiting
enzymatic
activity
Consistently,
local
pharmacological
administration
recombinant
CMA1
MCPT4
promoted
hypersensitivity
attenuated
upregulation
cytokines
chemokines
under
inflammation.
We
identified
CCL9
as
target
MCPT4.
Inhibition
recruitment
CD206
+
myeloid
alleviated
Our
work
reveals
new
chymases
preventing
suggests
therapeutic
avenues
for
treatment